{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:33:06Z","timestamp":1767598386153},"reference-count":20,"publisher":"Wiley","issue":"s71","license":[{"start":{"date-parts":[[2009,2,6]],"date-time":"2009-02-06T00:00:00Z","timestamp":1233878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Initially, immune (idiopathic) thrombocytopenic purpura (ITP) was considered to be a disease of increased platelet destruction. Consequently, treatments for ITP patients were focused on reducing the destruction of platelets. However, recent research on the pathogenesis of ITP points to a role of suboptimal platelet production, and this has led to the development of new treatment options which increase platelet production such as the novel thrombopoiesis\u2010stimulating agent, romiplostim. In two, multicentre, randomized, placebo\u2010controlled, double\u2010blinded, phase III trials, romiplostim was able to increase and sustain platelet counts in both splenectomized and non\u2010splenectomized patients. Eighty\u2010three per cent (69\/83) of the romiplostim\u2010treated patients achieved an overall platelet response compared with 7% (3\/42) of patients receiving placebo (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001; Cochran\u2013Mantel\u2013Haenszel test controlled for splenectomy and baseline concurrent ITP therapy). Patients from the romiplostim studies, with platelet counts below 50\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L, were able to enter a long\u2010term, open\u2010label, extension study. The results of the long\u2010term study showed that platelet counts above 50\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L were maintained for \u226510, \u226525 and \u226552 consecutive weeks by 78% (102\/131), 54% (66\/122) and 35% (29\/84) of patients, respectively. Romiplostim appears to be generally well tolerated and several patients have now been treated for more than 3\u2003yrs. Most adverse events tend to be mild to moderate in nature. Romiplostim provides a valid treatment option that may bring about a change in the way that patients with ITP are treated in the future. Further studies are now being undertaken in paediatric patients with ITP, patients with myelodysplastic syndrome and patients with chemotherapy\u2010induced thrombocytopenia.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01209.x","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T16:44:52Z","timestamp":1233765892000},"page":"20-25","source":"Crossref","is-referenced-by-count":13,"title":["Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura"],"prefix":"10.1111","volume":"82","author":[{"given":"Adrian","family":"Newland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,6]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010501"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.1.3.3"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04131.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03669.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1475"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0275"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/369533a0"},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1055\/s-0038-1642733","article-title":"c\u2010mpl, the thrombopoietin receptor","volume":"74","author":"Vainchenker W","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3241"},{"key":"e_1_2_8_11_2","article-title":"The novel thrombopoietic agent AMG 531 is effective in pre\u2010clinical models of chemo\/radiotherapy induced thrombocytopenia","volume":"46","author":"Hartley C","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054626"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2003.05.001"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.010"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06339.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60203-2"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.4.504"},{"key":"e_1_2_8_18_2","volume-title":"American Society of Hematology Annual Meeting December 8\u201310 2007","author":"Pullarkat VA","year":"2007"},{"key":"e_1_2_8_19_2","volume-title":"European Haematology Association Congress June 12\u201315 2008","author":"Newland A","year":"2008"},{"key":"e_1_2_8_20_2","volume-title":"AMG 531 Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","author":"US National Institutes of Health"},{"key":"e_1_2_8_21_2","volume-title":"Safety and Efficacy Study of AMG 531 to Treat ITP in Pediatric Subjects","author":"US National Institutes of Health"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01209.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01209.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T01:22:00Z","timestamp":1694481720000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01209.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,6]]},"references-count":20,"journal-issue":{"issue":"s71","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01209.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01209.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,6]]}}}